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α-7 nicotinic receptor and NMDA receptorThe Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) project
designed to facilitate the development of new drugs for the treatment of cognitive impairments in people
with schizophrenia, identiﬁed three drug mechanisms of particular interest: dopaminergic, cholinergic, and
glutamatergic. Galantamine is an acetylcholinesterase inhibitor and a positive allosteric modulator of the α7
nicotinic receptors. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist. There is evidence to
suggest that the combination of galantamine and memantine may be effective in the treatment of cognitive
impairments in schizophrenia. There is a growing body of evidence that excess kynurenic acid (KYNA) is
associated with cognitive impairments in schizophrenia. The α-7 nicotinic and the NMDA receptors may
counteract the effects of kynurenic acid (KYNA) resulting in cognitive enhancement. Galantamine and
memantine through its α-7 nicotinic and NMDA receptors respectively may counteract the effects of KYNA
thereby improving cognitive impairments. The Single Nucleotide Polymorphisms in the Cholinergic Receptor,
Nicotinic, Alpha 7 gene (CHRNA7), Glutamate (NMDA) Receptor, Metabotropic 1 (GRM1) gene, Dystrobrevin
Binding Protein 1 (DTNBP1) and kynurenine 3-monooxygenase (KMO) gene may predict treatment response
to galantamine and memantine combination for cognitive impairments in schizophrenia in the kynurenine
pathway.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Measurement and Treatment Research to Improve Cognition
in Schizophrenia (MATRICS) project designed to facilitate the
development of new drugs for the treatment of cognitive impairments
in people with schizophrenia, identiﬁed three drug mechanisms of
particular interest: dopaminergic, cholinergic, and glutamatergic
(Buchanan et al., 2007). Galantamine and memantine are FDA approved
medications to treat Alzheimer’s dementia. Galantamine is not only an
acetylcholinesterase inhibitor (AChEI), but also a positive allosteric
modulator of the α4β2 and α7 nicotinic receptors. In participants with
schizophrenia, galantaminehas shown improvement indelayedmemory
and attention (Schubert et al., 2006), the Hopkins Verbal Learning Test
(Lee et al., 2007), processing speed and verbal memory (Buchanan et al.,
2008) and social cognition (Lindenmayer and Khan, 2011). Encenicline,
an α7 nicotinic acetylcholine receptor agonist, was administered to
participants with schizophrenia for cognitive impairments in a 12-week
phase 2 randomized controlled trial (RCT). Out of 317 participants, 107
were on encenicline 0.27 mg, 105 were on encenicline 0.9 mg and 105System, 6501 N Charles St.,
: +1 410 938 3111.
uju@yahoo.com.
Inc. This is an open access article uwere on placebo. Encenicline 0.27 mg demonstrated signiﬁcant beneﬁ-
cial effects across multiple measures of cognition. The ﬁndings from this
ﬁrst promising study in schizophrenia need to be validated in large phase
3 studies. Although the CogState overall cognition indexwas statistically
superior to placebo, it had amodest effect size of 0.26 (Keefe et al., 2015).
Hence, with the AChEI, positive allosteric modulator of the α4β2 and α7
nicotinic receptor properties of galantamine (other AChEIs such as
donepezil and rivastigmine lack the latter twomechanismsof action) and
glutamatergic modulation bymemantine concurrently may signiﬁcantly
improve the effect size. Reduced activation of the glutamatergic signaling
pathways through the NMDA receptor has been hypothesized to be
associated with cognitive impairments in schizophrenia. Memantine is
anN-methylD-aspartate (NMDA) receptor antagonist. In ameta-analysis
of the three RCTs (N = 186), memantine signiﬁcantly (p = 0.002)
improved some cognitive functioning in people with schizophrenia
(Kishi and Iwata, 2013). Memantine 20 mg improved measures of
sensorimotor gating and mismatch negativity that were associated with
enhanced cognition in 84 participants with chronic psychotic disorders
(Swerdlow et al., 2016). In vivo (magnetic resonance spectroscopy)
evidence supported glutamatergic regulation ofmismatchnegativity and
verbal working memory function in schizophrenia (N = 45); authors
argued the potential role of memantine to target glutamatergic system
(Rowland et al., 2016). Add-on memantine 20 mg for 12 weeks in 64
inpatients with schizophrenia was signiﬁcantly effective in improving thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Finally, memantine 5–20 mg administered daily before
electroconvulsive therapy (ECT) has been shown to improve cognitive
performance after ECT (Abbasinazari et al., 2015; Alizadeh et al., 2015).
Authors argued the possible role of glutamatergic system for
ECT-associated cognitive impairments.
Targeting only one neurotransmitter system in the treatment of
cognitive impairments in schizophrenia was not associated with a
clinically meaningful efﬁcacy signal. Galantamine–memantine com-
bination (N = 53) was signiﬁcantly better for cognition than
donepezil–memantine (N = 61) in Alzheimer’s dementia patients
(Matsuzono et al., 2015). There is evidence to suggest that the
combination of galantamine and memantine may be effective in the
treatment of cognitive impairments in schizophrenia to broaden the
selective beneﬁts produced by either medication alone. In this paper,
the rationale of how this combination may act synergistically to
enhance cognition in schizophrenia was discussed (Koola et al., 2014).
To date, the cholinergic and glutamatergic systems have not been
concurrently targeted in people with schizophrenia to examine the
effectiveness for cognitive impairments in schizophrenia. A
mechanism- and computer-based quantitative systems pharmacology
model that combines biophysically realistic preclinical neurophysiol-
ogy and neuropharmacology with clinical information has been
suggested. In this model, combining antipsychotics, galantamine
and memantine showed a positive or neutral synergistic effect with
certain antipsychotics such as haloperidol and olanzapine in the
improvement of working memory, but a negative interaction with
quetiapine and aripiprazole (Geerts et al., 2015).
Excess kynurenic acid (KYNA) is associated with cognitive
impairments in schizophrenia (Wonodi and Schwarcz, 2010).
The α-7 nicotinic and the NMDA receptors may counteract the effects
of kynurenic acid (KYNA) resulting in cognitive enhancement
as shown in Fig. 1 (Wonodi and Schwarcz, 2010). Galantamine
and memantine through its α-7 nicotinic and NMDA receptors
respectively may counteract the effects of KYNA thereby improving
cognitive impairments (Koola et al., 2014).
The purpose of this paper is to discuss the rationale how the Single
Nucleotide Polymorphisms (SNPs) rs904952; rs2337980 in the
Cholinergic Receptor, Nicotinic, Alpha 7 gene (CHRNA7), rs6923492
in the Glutamate (NMDA) Receptor, Metabotropic 1 (GRM1) gene and
rs2275163, rs1053230 at the kynurenine 3-monooxygenase (KMO)
gene may predict treatment response to galantamine and memantine
combination to cognitive impairments in schizophrenia in the
kynurenine pathway.
2. Pathophysiology of kynurenine pathway in schizophrenia
Kynurenic acid (KYNA) is the only NMDA receptor antagonist in
the human central nervous system (Krystal et al., 1994; Stone, 1993).
The kynurenine pathway regulates the synthesis of KYNA by an
enzymatic cascade. KYNA has been identiﬁed as a potent antagonist of
the α-7 nicotinic and NMDA receptors (Hilmas et al., 2001; Parsons
et al., 1997). This antagonism may be associated with cognitive
impairment. There is more evidence supporting this hypothesis which
is the genes involved in the glutamatergic system (Collier and Li,
2003). KYNA concentration is increased in the prefrontal cortex of
people with schizophrenia; KYNA concentration correlated with
dopamine, acetylcholine and glutamate levels which reﬂect the
degree of cognitive impairment (Petrova and Dorofeykova, 2014).
KYNAmay be a valuable candidate for future therapeutic discovery for
the treatment of neurodegenerative diseases (Majláth et al., 2016)
such as schizophrenia.
Both NMDA and nicotinic receptors are implicated in the
pathophysiology of schizophrenia and Alzheimer’s dementia, twodisorders with cognitive impairments and increased KYNA concen-
tration (Baran et al., 1999; Erhardt et al., 2001; Nilsson et al., 2005;
Schwarcz et al., 2001). Increased brain KYNA concentration was found
in 11 postmortem Alzheimer’s dementia subjects compared to 13
controls (Baran et al., 1999). In a postmortem study comparing 30
subjects with schizophrenia and 31 controls, kynurenine and
kynurenate concentrations were signiﬁcantly higher in schizophrenia
brain (Schwarcz et al., 2001).
Signiﬁcantly increased cerebrospinalﬂuid (CSF)KYNAwas found in28
peoplewith schizophrenia compared to17healthy controls (Erhardt et al.,
2001). CSF KYNA was signiﬁcantly elevated in 90 participants with
schizophrenia compared to 49 healthy controls (Nilsson et al., 2005). CSF
KYNA was increased in 16 participants with schizophrenia compared to
29 healthy controls. In all participants kynurenine positively correlated
with KYNA (Linderholm et al., 2012). This is important because
kynurenine (KYN) crosses the blood brain barrier and KYNA does not
because of the polar structure. Quinolinic acid (QUIN), a neuroactive
metabolite of the kynurenine pathway, is normally presented in human
brain and CSF; QUIN is an agonist of NMDA receptor. CSF quinolinic acid
(QUIN) concentration from stable outpatients with schizophrenia (N =
22) and healthy controls (N = 26) was measured. No difference in CSF
QUIN concentration between patients and controls was observed. CSF
QUINwaspositively correlated toCSFKYNandCSFKYNA in schizophrenia
but not in controls. The CSF QUIN/KYNA ratio was signiﬁcantly lower in
schizophrenia than in controls. Authors argued for an over-activated and
imbalanced kynurenine pathway, favoring the production of KYNA over
QUIN in people with schizophrenia (Kegel et al., 2014). Finally, CSF KYN
and KYNA concentrations were elevated in 23 participants with
schizophrenia compared to 37 healthy volunteers (Schwieler et al., 2015).3. Potential treatment mechanisms targeting kynurenine pathway
The kynurenine pathway is controlled by the immune system.
Stimulation of the cholinergic system downregulates the inﬂammatory
immune response which is known as cholinergic anti-inﬂammatory
pathway (van Westerloo and van der Poll, 2005). Alpha-7 nicotinic
receptor antagonismof KYNAmay lead to the inhibition of the cholinergic
anti-inﬂammatory pathway. In addition to the immunological mecha-
nism, selective cyclooxygenase-2 (COX-2) inhibitors reduce KYNA
concentration by a prostaglandin-mediated mechanism (Müller et al.,
2005; Schwieler et al., 2005). COX inhibition has differential effects on
kynurenine metabolism: while COX-1 inhibitors increase the levels of
KYNA, COX-2 inhibitors decrease them. Therefore, psychotic symptoms
and cognitive impairments observed during therapy with COX-1
inhibitors had COX-1 mediated increase of KYNA (Clunie et al., 2003;
Schwieler et al., 2005; Tharumaratnam et al., 2000). COX-2 inhibition
directly attenuates inﬂammation-induced inhibition of long-term poten-
tiation, an animal model of cognition (Cumiskey et al., 2007;Müller et al.,
2005). Animals with a genetic over expression of COX-2 had more
prominent deﬁcits in cognition, which were attenuated by a selective
COX-2 inhibitor (Melnikova et al., 2006).
There are several studies suggestive of the anti-inﬂammatory
properties of galantamine (Giunta et al., 2004; Ji et al., 2014;
Wenk et al., 2002). There is evidence that galantamine alleviated
inﬂammation in high-fat diet fed mice (Satapathy et al., 2011). In
mice, inhibition of brain acetylcholinesterase suppressed systemic
inﬂammation through a central muscarinic receptor-mediated and
vagal- andα-7nAChR-dependentmechanism. Authors concluded that
a clinically used centrally-acting acetylcholinesterase inhibitor can be
utilized to suppress abnormal inﬂammation to therapeutic advantage
(Pavlov et al., 2009). Similarly, there are several studies that have
reported the anti-inﬂammatory role of memantine (Cho et al., 2013;
Lindblad et al., 2012). Memantine attenuated morphine addictive
Fig. 1. Kynurenine pathway and cognitive impairments in schizophrenia and the association of α-7 nicotinic and the NMDA receptors. Kynurenine pathway metabolism is initiated
by the oxidative ring opening of tryptophan by both indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase. In the brain, the metabolite L-kynurenine is enzymatically
converted in microglial cells and astrocytes. In schizophrenia, there is a persistent reduction of microglial kynurenine 3-monooxygenase activity, along with increased L-kynurenine
inﬂux from the circulation. This results in increased kynurenic acid formation in astrocytes (Wonodi and Schwarcz et al., 2010). Galantamine and memantine through its α-7
nicotinic and NMDA receptors respectively may counteract the effects of KYNA thereby improving cognitive impairments.
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effects in rodents (Chen et al., 2012).
Early developmental increase in brain KYNA was associated with
cognitive impairments in adult rodents which were reversed with
galantamine (Alexander et al., 2013). Kynurenine aminotransferase II
(KAT II) inhibitor (Fig. 1) restored nicotine-evoked glutamatergic
activity in the cortex of rats and reduced brain KYNA concentration
(Koshy Cherian et al., 2014). KAT II inhibitor reduced brain KYNA to
28% of baseline concentration, and prevented amphetamine- and
ketamine-induced disruption of auditory gating and improved
performance in a sustained attention task. It also prevented
ketamine-induced disruption of performance in a working memory
task and a spatial memory task in rodents and nonhuman primates,
respectively (Kozak et al., 2014). Finally, the reduction of psycho-
pathological symptoms and variations in 3-hydroxykynurenine levels
(3-OHKYN; Fig. 1) as well as changes in KYNA/3-OHKYN
and kynurenine/KYNA ratios are exciting for kynurenine pathway
modiﬁcations. This may lead to novel target engagement for future
antipsychotics discovery and development (Karakuła-Juchnowicz
et al., 2014). Last, a 'two hit model' of schizophrenia to target both
the glutamatergic system and the inﬂammatory system has been
proposed (Muller and Schwarz, 2006).4. Pharmacogenetics of kynurenine pathway
There are data suggestive that genetic factors have a signiﬁcant role in
the etiology of cognitive impairment in schizophrenia (Bilder et al., 2011;
Glahn et al., 2007). Indoleamine 2,3-Dioxygenase (IDO), tryptophan
2,3-dioxygenase (TDO) and kynurenine 3-monooxygenase (KMO) genes
are associated with cognitive impairments in schizophrenia (Aoyama
et al., 2006; Miller et al., 2004). IDO, TDO and KMO genes may be of
particular interestbecauseofKYNAandtheassociationwithα-7nicotinicand
NMDA receptors. Speciﬁc SNPs associated with IDO and TDO genes are not
known. CHRNA7 was the candidate gene of the α7nAChR in the NIMH
Schizophrenia Genetics Initiative families (Freedman et al., 2001). The
rationale of the SNPs that are proposed as predictors of treatment responseto the combination of galantamine and memantine is shown in Table 1.
rs2275163 and rs1053230 are the KMOgene SNPs, rs904952 and rs2337980
in CHRNA7 gene, rs6923492 at the Glutamate (NMDA) Receptor, Metabo-
tropic 1 (GRM1) and rs1018381, rs2619539, rs3213207, rs2619538 and
rs760761 in the Dystrobrevin Binding Protein 1 (DTNBP1) gene. These SNPs
are likely to predict response throughα7nAChR and the NMDA receptors as
shown in Fig. 1.5. Conclusions and future directions
The combination of antipsychotic/s, galantamine and memantine
may target dopaminergic, cholinergic and glutamatergic systems
concurrently to improve cognitive improvements in schizophrenia
(Buchanan et al., 2007; Geerts et al., 2015; Koola et al., 2014).
Measuring KYNA and L-kynurenine concentrations could be the novel
target engagement to measure the degree of cognitive impairment and to
monitor prognosis with the treatment. There are ongoing studies to test this
hypothesis (clinicaltrials.gov identiﬁerNCT02234752).More stringent inclusion
and exclusion criteria on antipsychotics (Geerts et al., 2015), anticholinergic
treatment (Geerts et al., 2015; Wijegunaratne et al., 2014), careful analysis of
smokingstatus (Geertsetal., 2015),payingmoreattention topharmacokinetics
and pharmacodynamics and using SNPs to predict response may enable the
ﬁeldtodetectclinicallymeaningfuleffectivenesssignal.KYNAandL-kynurenine
concentrations decrease with anti-inﬂammatory treatment. Future studies are
warranted to examine speciﬁc SNPs that may predict response in the
kynurenine pathwaywith the anti-inﬂammatory treatment.Role of Funding Source
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Table 1
Single nucleotide polymorphisms that may predict response to treatment through the α-7nAch and the NMDA receptors in the kynurenine pathway model.
Studies Gene SNPs Cognition Sample
size
Effect size P value Function
Aoyama et al., 2006 Kynurenine
3-monooxygenase
(KMO) gene
rs2275163–rs1053230–rs1053183
rs2275163–rs1053230–rs1053183
Haplotype distributions of KMO gene
Independent sample conﬁrmation analysis
SZ = 465
HC = 440
SZ = 480
HC = 448
Odds ratio =
4.1
0.00025
0.7
KYNA, a metabolite of
the kynurenine pathway
of tryptophan degradation,
is an antagonist at
N-methyl-D-aspartate and α7
nicotinic acetylcholine
receptors and modulates glutamate,
dopamine, and acetylcholine signaling
NMDA receptor and α7nAChR
Holtze et al., 2012 KMO gene rs1053230 CSF concentrations of KYNA SZ = 17
HC = 50
0.002 NMDA and α7 nicotinic
acetylcholine receptors
Wonodi et al., 2011
Wonodi et al., 2014
KMO gene rs2275163
rs2275163
Predictive pursuit and visuospatial
working memory endophenotypes
Deﬁcits in general neuropsychological performance
SZ = 248
HC = 228
SZ = 150
HC = 95
0.61
0.57
0.005
b0.001
NMDA and α7 nicotinic
acetylcholine receptors
Freedman et al., 2001
Bakanidze et al., 2013
chromosome
15q13-14 locus
of the Cholinergic
Receptor, Nicotinic,
Alpha 7
(CHRNA7 gene)
rs904952 Visual backward masking (VBM),
a sensitive test for early visual
information processing
50 families
SZ = 224
HC = 224
0.48 b0.007
0.009
Alpha-7 nicotinic acetylcholine
receptor
Rigbi et al., 2011 CHRNA7 rs2337980 Attention in Matching Familiar
Figures Test and Continuous Performance Task
31 female
smokers
0.01 Alpha-7 nicotinic acetylcholine
receptor
Tregellas et al., 2011 CHRNA7 rs3087454 Posterior cingulate default network
activity
SZ = 16 0.024 Alpha-7 nicotinic acetylcholine
receptor
Liu et al., 2009 CHRNA7 rs3087454 rs1355920 Auditory oddball task SZ = 20
HC = 43
r = 0.53 0.001 Alpha-7 nicotinic acetylcholine
receptor
Greenwood et al., 2011 Glutamate Receptor,
Metabotropic 1 (GRM1)
rs6923492 Verbal reasoning
Spatial memory
SZ = 534
from 130
families
0.001 NMDA receptor
Burdick et al., 2006 Dystrobrevin Binding
Protein 1 (DTNBP1)
rs1018381 Wide Range Achievement
Test, Digit Span, Continuous
Performance Test,
California Verbal Learning Test, Controlled
Oral Word Association Test and Trail
Making Tests A&B
SZ = 213
HC = 126
0.0008 NMDA receptor
Donohoe et al., 2007 DTNBP1 rs2619539
rs3213207
rs2619538
Working memory SZ = 52 0.009 NMDA receptor
Baek et al., 2012 DTNBP1 rs760761 rs1018381 Attention
vigilance
SZ = 122
HC = 119
b0.001 NMDA receptor
Varela-Gomez et al., 2015 DTNBP1 rs2619539
rs3213207
Working memory
(rs2619539; p = 0.01)
Verbal memory (rs3213207; p = 0.02)
FEP = 238
HC = 47
NMDA receptor
SZ = schizophrenia, HC = healthy controls, FEP = ﬁrst episode psychosis; r = correlation coefﬁcient.
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